Literature DB >> 1609046

Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia.

M H Chakos1, D I Mayerhoff, A D Loebel, J M Alvir, J A Lieberman.   

Abstract

The incidence and correlates of extrapyramidal symptoms (EPS) in neuroleptic treatment of schizophrenic patients have been reported for chronic patients but not for first-episode patients. We examined the incidence and correlates of extrapyramidal symptoms in a cohort of 70 treatment-naive patients who received fluphenazine at 20-40 mg/day for the first 10 weeks of treatment. Thirty-four percent of our sample developed parkinsonism, 18 percent developed akathisia, and 36 percent developed dystonia. Acute EPS were associated with greater baseline psychopathology. Acute EPS were also associated with better treatment outcome in terms of time to and level of remission. These findings suggest that the EPS response of neuroleptic-naive patients may differ from that of chronically ill patients and that acute EPS status may be an indicator of pharmacologic responsivity in this group.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1609046

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  18 in total

Review 1.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

2.  The role of estrogen in schizophrenia.

Authors:  M V Seeman
Journal:  J Psychiatry Neurosci       Date:  1996-03       Impact factor: 6.186

3.  Detection, Assessment, and Management of Schizophrenia in an Andean Population of South America: Parkinsonism Testing and Transcranial Ultrasound as Preventive Tools.

Authors:  Mara Balda; Maria Calvó; Eduardo Padilla; Gonzalo Guerrero; Juan Molina; Nestor V Florenzano; Danielle Kamis; Javier I Escobar; C Robert Cloninger; Gabriel de Erausquin
Journal:  Focus (Am Psychiatr Publ)       Date:  2015

4.  Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis.

Authors:  J F Guest; R F Cookson
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

Review 5.  Adverse effects of antipsychotic drugs.

Authors:  A K Malhotra; R E Litman; D Pickar
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

6.  Sex and laterality differences in parkinsonian impairment and transcranial ultrasound in never-treated schizophrenics and their first degree relatives in an Andean population.

Authors:  Danielle Kamis; Lee Stratton; María Calvó; Eduardo Padilla; Néstor Florenzano; Gonzalo Guerrero; Beatriz Molina Rangeon; Juan Molina; Gabriel A de Erausquin
Journal:  Schizophr Res       Date:  2015-02-27       Impact factor: 4.939

7.  Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants.

Authors:  Hsien-Yuan Lane; Yue-Cune Chang; Chih-Chiang Chiu; Sue-Hong Lee; Cher-Yeang Lin; Wen-Ho Chang
Journal:  Psychopharmacology (Berl)       Date:  2003-12-09       Impact factor: 4.530

8.  Prediction of Neurocognitive Deficits by Parkinsonian Motor Impairment in Schizophrenia: A Study in Neuroleptic-Naïve Subjects, Unaffected First-Degree Relatives and Healthy Controls From an Indigenous Population.

Authors:  Juan L Molina; Gabriela González Alemán; Néstor Florenzano; Eduardo Padilla; María Calvó; Gonzalo Guerrero; Danielle Kamis; Lee Stratton; Juan Toranzo; Beatriz Molina Rangeon; Helena Hernández Cuervo; Mercedes Bourdieu; Manuel Sedó; Sergio Strejilevich; Claude Robert Cloninger; Javier I Escobar; Gabriel A de Erausquin
Journal:  Schizophr Bull       Date:  2016-03-18       Impact factor: 9.306

9.  Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients.

Authors:  Ana Alkelai; Lior Greenbaum; Amihai Rigbi; Kyra Kanyas; Bernard Lerer
Journal:  Psychopharmacology (Berl)       Date:  2009-08-13       Impact factor: 4.530

10.  Managing antipsychotic-induced acute and tardive dystonia.

Authors:  M Raja
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.